Multi-antibiotic-resistant Gram-negative pathogens are becoming more prevalent and an association exists between chromosomally conferred fluoroquinolone resistance and the presence of plasmidborne resistances, such as extended spectrum b-lactamases. This link is not wholly explained by strain spread or the presence of fluoroquinolone-modifying enzymes. Plasmid-encoded toxin-antitoxin addiction systems enforce plasmid maintenance in bacteria and, like fluoroquinolones, some toxins target DNA gyrase. Bacteria can develop resistance to these toxins, which would free the cell of the plasmid addiction and allow it to ditch the 'excess baggage'. We hypothesize that these plasmid-encoded gyrase toxins might contribute to, or predispose towards, clinically significant fluoroquinolone resistance, and that the plasmid-encoded quinolone resistance determinant, Qnr, may facilitate this. Establishing the extent and mechanisms of cross-resistance to toxins and fluoroquinolones will aid the management of resistance and may contribute to the development of novel antimicrobials.
Multi-antibiotic-resistant Gram-negative pathogens are becoming more prevalent and are threatening public health in the face of a dearth of new antibiotics against them. 1 Resistance to the widely used fluoroquinolone class of antibacterials occurs in 15-20% of >16 000 bacteraemias caused by Escherichia coli in the UK per annum, and is similarly prevalent in other common Enterobacteriaceae such as Klebsiella spp. and Enterobacter spp.
2 In many bacterial species there is a strong association between clinically significant fluoroquinolone resistance, contingent on chromosomal mutation, and the carriage of plasmids, including those that encode extended-spectrum b-lactamases. 3, 4 This correlation between chromosomal and plasmid-mediated resistances occurs also in Gram-positive species, such as in successful strains of methicillin-resistant Staphylococcus aureus 5 and highly gentamicin-resistant Enterococcus faecalis. 6, 7 Moreover, as multiple strains of many species show this association it is apparent that clonal strain success is not the only factor involved, raising the question of what else is driving this relationship.
Fluoroquinolones target topoisomerase IV and DNA gyrase and, until recently, resistance was considered to be entirely mediated by chromosomal mutations. Despite this, conflicting data exist amongst clinical isolates for a link between hypermutability and the emergence of fluoroquinolone resistance. 8, 9 Most clinically significant fluoroquinolone resistance is are associated with mutations in the quinolone resistance determining regions (QRDRs) of gyrA-gyrB or parC-parE (encoding DNA gyrase and topoisomerase IV subunits, respectively). 10 Relatively little is known of the importance of gyr and par mutations outside of the QRDRs, but these have recently been associated with fluoroquinolone resistance. 11, 12 This raises the possibility that changes at other sites in DNA gyrase or topoisomerase IV could play either a direct role in fluoroquinolone resistance or in predisposition towards its development. In E. coli little consideration has been given to such possibilities thus far.
Low-level and incremental fluoroquinolone resistance can also be conferred by chromosomal mutations that cause overexpression of the Acr system, and can increase antibiotic efflux. 13, 14 Recently, other mechanisms of low-level fluoroquinolone resistance associated with plasmids have impacted upon our understanding. The gene encoding QnrA has been found on multiresistance plasmids in Enterobacteriaceae worldwide. 15, 16 QnrA interacts with DNA gyrase and topoisomerase IV, 17, 18 protecting against fluoroquinolone binding and conferring a modest increase in fluoroquinolone MICs. This widens the mutant selection window by increasing the mutant prevention concentration 10-fold, facilitating an increase in the frequency of the emergence of clinically significant high-level resistance via QRDR mutations. 19 The occurrence of QnrA on multiresistance plasmids might explain the association between high-level quinolone resistance and plasmid-mediated resistances. However, large variations in Qnr prevalence have been reported worldwide, and large European surveys have found qnr genes in only 0.5% of quinolone-resistant isolates in France, and of quinolone-or cephalosporin-resistant isolates in Germany, 15 and 3% of cephalosporin-resistant Enterobacteriaceae in the UK. 20 Thus QnrA appears to be a relatively minor factor contributing to the association between fluoroquinolone resistance and multiresistance. The global prevalence of other Qnr determinants such as QnrB and QnrS 15 is currently unknown. A further plasmid-mediated determinant-a novel variant of a common aminoglycoside-acetyltransferase [aac(6 0 )-Ib-cr]--was found in 51% of 71 ciprofloxacin-resistant clinical isolates from Shanghai. This variant modifies ciprofloxacin and confers a 4-fold decrease in ciprofloxacin susceptibility, in addition to kanamycin, tobramycin and amikacin resistance. 21 Like QnrA, this mechanism also eases the development of higher-level fluoroquinolone resistance in E. coli. Despite its high prevalence in the sample set tested, its global prevalence is currently unknown although it has been reported in North America and China. 19 Only 21% of the 466 ciprofloxacinresistant E. coli referred to the Antibiotic Resistance Monitoring and Reference Laboratory (ARMRL) at the Health Protection Agency's Centre for Infections in London, between 2004 and 2006, were resistant to both amikacin and tobramycin compared with 7% of the 168 ciprofloxacin-susceptible isolates. Thus, even when the prevalences of QnrA and AAC(6')-Ib-cr are considered together, these plasmidic mechanisms are unlikely to account entirely for the association between ciprofloxacin resistance and multiresistance in E. coli or other bacteria. It is likely that other factors also contribute to this association.
Successful strains of pathogenic bacteria often carry multiple plasmids and theoretically are disposed to elevated rates of plasmid loss as a result of partitioning mistakes during cell division. In reality plasmid loss may be prevented by plasmid-encoded 'addiction systems' [also called post-segregation killing or toxin-antitoxin (TA) systems], which work as TA pairs. The greater longevity of the toxin compared with the antitoxin means that daughter cells that lose the plasmid are no longer able to produce the antitoxin, and become exposed to the residual toxin with fatal consequences. 22 TA systems not only enforce plasmid stability, but also act to exclude other plasmids of the same compatibility group. While they have been known for some time, 23, 24 they have only been identified on resistance plasmids relatively recently. 25 At least six plasmid-mediated TA systems have been identified in E. coli. 22 The molecular target of three of these systems has been identified. The CcdB and ParE toxins (distinct from the ParE subunit of topoisomerase IV) from plasmids F and RK2, respectively, both target and interact with the GyrA subunit of DNA gyrase. 26, 27 In this functional respect, they resemble fluoroquinolones and QnrA. While the CcdB toxin and its antitoxin CcdA form a tight complex, 28 exposure to even a small amount of free toxin would be analogous with exposure to subinhibitory concentrations of an antibiotic and might select for resistance. Resistance to such toxins would potentially allow the bacterium to circumvent plasmid addiction and ditch the 'excess baggage'. It would even allow the bacterium to acquire a new plasmid of the same compatibility group, permitting gene flux amongst the total cellular DNA-providing an advantage in competitive and stressful environments. Indeed, resistance to these 'addictive' and 'parasitic' 22 toxins can occur via changes in the CcdB toxin itself, which can attenuate the toxic effect of the protein. 29, 30 In addition, target changes can occur; an amino acid substitution in the GyrA protein (Arg-462!Cys) confers resistance to CcdB, but this position is situated far from the QRDR of GyrA, and the Cys substitution does not affect fluoroquinolone susceptibility. 31 Nevertheless, the small number of toxin resistance mutations so far described is unlikely to be comprehensive, and it is possible that amino acid substitutions at non-QRDR sites in DNA gyrase may provide a degree of cross-resistance to both toxins and fluoroquinolones, providing a further putative link between fluoroquinolone resistance and plasmidic resistances. At least one route of toxin-fluoroquinolone cross-resistance is already known; E. coli can resist or tolerate the CcdB toxin via up-regulation of the intrinsic chromosomally encoded protein GyrI, which also confers decreased susceptibility to fluoroquinolones. 32, 33 Like QnrA, GyrI interacts with DNA gyrase and inhibits formation of a drug-gyrase-DNA ternary complex. By analogy, QnrA, a DNA gyrase inhibitor known to confer quinolone resistance, might also influence the development of toxin resistance. Moreover, given that quinolones are synthetic compounds, it seems fortuitous that a natural protein, Qnr, confers resistance to them, and tempts speculation that toxin resistance could be one of the (currently unknown) true physiological roles of Qnr-like proteins. A precedent for protection against such self-encoded or 'self-imposed' pressure is set by another pentapeptide repeat protein related to Qnr, McbG, which also inhibits DNA gyrase, and contributes to immunity to the colicin 'microcin B17', [34] [35] [36] effectively protecting bacteria producing this toxin from self-inhibition.
Clearly there are multiple natural and synthetic inhibitors of DNA gyrase, each with different effects. These can be encoded by the cell's own genome or by the genomes of other cells, or they may be present as synthetic antibacterials. To date, there is no simple explanation for the association between multiple plasmid-mediated resistances and high-level fluoroquinolone resistance. It is likely to be multifactorial, and we propose that this association may, in part, represent self-imposed resistance development, exacerbated by the presence of multiple plasmids which may encode TA systems that target DNA gyrase-which is a critical target for fluoroquinolone antibiotics. Importantly, the effect of mechanisms developed to resist DNA-gyrase-targeting toxins on the development of mutations affecting fluoroquinolone resistance remains unknown. However, the hypothesis could be tested if plasmids encoding gyrase-targeting toxins were identified and the frequency of the emergence of fluoroquinoloneresistant mutants determined in the absence and presence of the plasmids. But in a naive host this may be complicated if mutational toxin resistance is required in a multistep pathway before predisposition towards quinolone resistance is detectable. Further additional interesting questions include the matter of plasmid stability and the functional relationship between Qnr and GyrI for the evolution and maintenance of resistance. 'Plasmid addiction' toxins are a focus for the development of novel antimicrobials through structural studies, 37, 38 and a novel bacteriophage delivery technology to facilitate their use has been developed. 39 It is of utmost importance to understand the development of resistance to these toxins in order to assess their efficacy or longevity as potential novel agents. In addition, the toxins have fundamental relevance, not only to multiresistant E. coli, which is a major pathogen causing increasing public health concern as it becomes more multiresistant, but also to other Gram-negative and Gram-positive pathogens where plasmidic resistance such as high-level gentamicin-resistance is associated with fluoroquinolone resistance.
